Abstract

Bronchodilators are used internationally for 50–80% of patient swith cystic fibrosis (CF). No published data exists on co-morbid asthma or bronchodilator use in New Zealand (NZ). Bronchodilator responsiveness has been reported in≥50% of patients with CF. Aim: To determine the prevalence of co-morbid asthma in the adult CF population of Wellington, NZ.
Original languageEnglish
Pages1
Publication statusPublished - 2015
EventThoracic Society of Australia & New Zealand and the Australian & New Zealand Society of Respiratory Science Annual Scientific Meeting 2015 - Gold Coast, Australia
Duration: 27 Mar 201501 Apr 2015
https://onlinelibrary.wiley.com/toc/14401843/2015/20/S2 (Abstracts)

Conference

ConferenceThoracic Society of Australia & New Zealand and the Australian & New Zealand Society of Respiratory Science Annual Scientific Meeting 2015
CountryAustralia
CityGold Coast
Period27/03/1501/04/15
Internet address

Fingerprint Dive into the research topics of 'The prevalence of co-morbid asthma in a New Zealand cycstic fibrosis population'. Together they form a unique fingerprint.

Cite this